WHWK
Whitehawk Therapeutics, Inc. Common StockWHWK
WHWK
About: Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Employees: 19
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,525% more call options, than puts
Call options by funds: $65K | Put options by funds: $4K
68.15% more ownership
Funds ownership: 60.64% [Q4 2024] → 128.79% (+68.15%) [Q1 2025]
19% more capital invested
Capital invested by funds: $47.2M [Q4 2024] → $56.4M (+$9.15M) [Q1 2025]
6% less funds holding
Funds holding: 53 [Q4 2024] → 50 (-3) [Q1 2025]
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
25% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for WHWK.
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference
MORRISTOWN, N.J. , May 28, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today its presentation at the Jefferies 2025 Global Healthcare Conference, taking place June 3-5, 2025, in New York City, NY.
Neutral
PRNewsWire
3 weeks ago
Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit
MORRISTOWN, N.J. , May 21, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on May 28, 2025, at 2:30 PM ET.
Neutral
PRNewsWire
1 month ago
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights
MORRISTOWN, N.J. , May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the first quarter ended March 31, 2025, and provided recent corporate progress.
Neutral
PRNewsWire
2 months ago
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
MORRISTOWN, N.J. , March 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced the successful closing of the divestiture of Aadi Subsidiary, Inc. ("Aadi Sub") to Kaken Pharmaceuticals ("Kaken") for a cash payment of $100 million plus certain customary adjustments, completing the strategic transformation first announced in December 2024.
Neutral
Seeking Alpha
2 months ago
Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript
Whitehawk Therapeutics Inc. (NASDAQ:WHWK ) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Audrey Gross - Head of Corporate Communications Dave Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications David Dornan - Chief Scientific Officer Conference Call Participants Greg Weasner - TD Securities Liang Cheng - Jefferies Operator Ladies and gentlemen, thank you for standing by. Welcome to Whitehawk Therapeutics Fourth Quarter and Full Year 2024 Earnings Call.
Neutral
PRNewsWire
2 months ago
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision.
Charts implemented using Lightweight Charts™